Patents by Inventor Mark HELLMICH

Mark HELLMICH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY
    Publication number: 20190336462
    Abstract: In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-?-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.
    Type: Application
    Filed: April 23, 2019
    Publication date: November 7, 2019
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Mark HELLMICH, Jia ZHOU, Csaba SZABO
  • Use of hydrogen sulfide synthesis inhibitors for cancer therapy
    Patent number: 10335382
    Abstract: In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-?-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: July 2, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Mark Hellmich, Jia Zhou, Csaba Szabo
  • Apigenin analogs, compositions, and methods related thereto
    Patent number: 9868715
    Abstract: Certain embodiments are directed to apigenin analogues or derivatives. In certain aspects, the derivatives are developed as cystathionine-beta-synthase (CBS) inhibitors. In certain aspects, the derivatives are used as anticancer or anti-inflammatory agents. Certain embodiments are directed methods of treating or compositions used to treat fibrosis and cancers. In certain aspects one or more compounds described herein can be administered to a subject to treat pancreatic fibrosis, liver fibrosis, pancreatic cancer, colon cancer, breast cancer, brain tumors, head/neck cancer, prostate and lung cancers as well as other inflammation.
    Type: Grant
    Filed: April 18, 2015
    Date of Patent: January 16, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS
    Inventors: Jia Zhou, Mark Hellmich, Csaba Szabo
  • APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO
    Publication number: 20170204078
    Abstract: Certain embodiments are directed to apigenin analogues or derivatives. In certain aspects, the derivatives are developed as cystathionine-beta-synthase (CBS) inhibitors. In certain aspects, the derivatives are used as anticancer or anti-inflammatory agents. Certain embodiments are directed methods of treating or compositions used to treat fibrosis and cancers. In certain aspects one or more compounds described herein can be administered to a subject to treat pancreatic fibrosis, liver fibrosis, pancreatic cancer, colon cancer, breast cancer, brain tumors, head/neck cancer, prostate and lung cancers as well as other inflammation.
    Type: Application
    Filed: April 18, 2015
    Publication date: July 20, 2017
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jia ZHOU, Mark HELLMICH, Csaba SZABO
  • USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY
    Publication number: 20160095831
    Abstract: In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-?-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Mark HELLMICH, Jia ZHOU, Csaba SZABO